Notably, ~1% of the cohort had V600E/class I alterations yet only 6 patients were treated with BRAF inhibitors While it is unclear as to why BRAF inhibitors were infrequently used in this population, one explanation may be the underwhelming efficacy of BRAF inhibition in management of GI cancers when compared to melanoma. This evidence concerns the gene BRAF and melanoma.